Opinion
Video
Author(s):
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Patients With CLL Place the Most Value on Treatments That Prolong PFS
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes
Revisit the OncLive On Air Episodes From February 2024
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
Observational Study Finds Progression Common in Lower-Risk Myelofibrosis
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma
Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis